Inhibrx Inc


Market Cap$1.8B

Compare Inhibrx

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Inhibrx IncInhibrx Inc-7.40%-555%-4.8
marketMarket Avg54.31.27%32%-1.3
HealthcareHealthcare Avg39.11.36%17%7.21.3

Current Fair Value

96.2% downside

Overvalued by 96.2% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.80 Billion
Enterprise Value$1.73 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-5.12
Outstanding Shares52,401,941
Avg 30 Day Volume352,087


Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-7.44
Price to Sales-
Price to Book Ratio-
Enterprise Value to Revenue960.6
Enterprise Value to EBIT-7.89
Enterprise Value to Net Income-8
Total Debt to Enterprise0.12
Debt to Equity4.83

Revenue Sources

No data

ESG Score

No data

About Inhibrx Inc

88 employees

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...